November 28, 2022 News by Margarida Maia, PhD How Nasal Foralumab Affects Healthy Immune System: Study Foralumab nasal spray, an experimental therapy by Tiziana Life Sciences thatās being tested for multiple sclerosis and other autoimmune and nervous system diseases, was found to be safe and able to modulate the immune system in healthy volunteers, a study has found. Researchers failed to detect antibodies…
June 16, 2022 News by Marisa Wexler, MS 2nd SPMS Patient Sees Clinical Gains With Foralumab Treatment Treatment with foralumab nasal spray resulted in marked clinical improvements after three months in the second secondary progressive multiple sclerosis (SPMS) patient treated under a single-patient access program. The findings were generally consistent with those seen in the first SPMS patient and supported a decision by the U.S. Food…
April 12, 2022 News by Marta Figueiredo, PhD 8 More SPMS Patients Cleared for Foralumab Nasal Spray Treatment Based on findings from the first two secondary progressive multiple sclerosis (SPMS) patients givenĀ foralumab nasal spray, an experimental therapy, the U.S. Food and Drug Administration (FDA) has approved starting treatment in up to eight other patients under a special access program. Those enrolled in this intermediate-size expanded access…
March 15, 2022 News by Marta Figueiredo, PhD Foralumab as Nasal Spray Safely, Effectively Treats 1st SPMS Patient Six months of treatment with foralumab, anĀ experimental nasal spray, safely and effectively improved motor and cognitive function while easing immune activation and inflammatory responses in a person with secondary progressive multiple sclerosisĀ (SPMS), Tiziana Life Sciences, the therapyās developer, announced. The patient ā the first with MS to…
January 11, 2022 News by Lindsey Shapiro, PhD 2nd Patient to Get Foralumab Nasal Spray After Promising First Data Following promising data from the first participant in a special access program that’s testingĀ foralumabĀ nasal spray forĀ secondary progressive multiple sclerosis (SPMS), a second patient has been enrolled in the ongoing evaluation. The first patient in the study, by Tiziana Life Sciences, the nasal spray’s developer, was halfway through…
June 7, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: Nasal DMT, VR for Gait, Brain Stimulation, Amino Sugars Nasal Foralumab Led to Promising Immune Effects in Phase 1 Trial It sure would be nice to have a nasal spray to treat MS, but this research is still in its early stages. This study looked only at the safety and preliminary effectiveness of nasal foralumab on healthy volunteers.